Spots Global Cancer Trial Database for UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer

Official Title: Phase II Trial of Adding UFUR to Non-small-cell Lung Cancer Patients Treated With Iressa

Study ID: NCT01037998

Conditions

Non-Small-Cell Lung Cancer

Interventions

UFUR and Iressa

Study Description

Brief Summary: Iressa \[epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI)\] has been reported to activity against Non-small-cell Lung Cancer (NSCLC) failed previous chemotherapy. UFUR was found to have anti-angiogenesis effect when long term treatment was given. Combination of EGFR-TKI and anti-angiogenesis agents is a novel treatment.

Detailed Description: Iressa is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It is an orally active agent for advanced non-small-cell lung cancer (NSCLC) in those who have failed a previous platinum-based regimen and taxane treatment. UFUR (Tegafur/Uracil) is effective agent against chemo-naïve NSCLC. It has anti-angiogenesis effect when used as long-term low dose treatment. Present phase II randomized clinical trial is designed to answer whether or not adding an oral anti-angiogenesis agent (UFUR), that has low toxicity profiles when long term use, to EGFR-TKI (Iressa) could increase patients survival and response rate.